Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease
Tracking Information | |
---|---|
First Received Date ICMJE | April 7, 2004 |
Last Updated Date | October 14, 2011 |
Start Date ICMJE | February 2004 |
Estimated Primary Completion Date | December 2011 (final data collection date for primary outcome measure) |
Current Primary Outcome Measures ICMJE |
|
Original Primary Outcome Measures ICMJE |
|
Change History | Complete list of historical versions of study NCT00080756 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures ICMJE | |
Original Secondary Outcome Measures ICMJE | |
Current Other Outcome Measures ICMJE | |
Original Other Outcome Measures ICMJE | |
Descriptive Information | |
Brief Title ICMJE | Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease |
Official Title ICMJE | Biomarkers, Breast Density And Risk Reduction Perspectives In BRCA Carriers |
Brief Summary | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Deslorelin combined with low-dose add-back estradiol and testosterone (given to replace hormones suppressed by deslorelin) may be effective in preventing breast cancer in at-risk women. PURPOSE: This phase II trial is studying how well giving deslorelin together with estradiol and testosterone works in preventing breast cancer in premenopausal women who are at high risk for this disease. |
Detailed Description | OBJECTIVES:
OUTLINE: This is a pilot study. Participants receive intranasal deslorelin, estradiol, and testosterone once daily for 6-10 months. Quality of life is assessed at baseline, at 6 and 10 months, and then every 6 months until 2 years after study registration. PROJECTED ACCRUAL: A total of 10 participants will be accrued for this study. |
Study Type ICMJE | Interventional |
Study Phase | Phase 2 |
Study Design ICMJE | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
Condition ICMJE |
|
Intervention ICMJE |
|
Study Arm (s) | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
Recruitment Information | |
Recruitment Status ICMJE | Active, not recruiting |
Estimated Enrollment ICMJE | 10 |
Completion Date | |
Estimated Primary Completion Date | December 2011 (final data collection date for primary outcome measure) |
Eligibility Criteria ICMJE | DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Age
Sex
Menopausal status
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY: Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
|
Gender | Female |
Ages | 21 Years to 48 Years |
Accepts Healthy Volunteers | Yes |
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects |
Location Countries ICMJE | United States |
Administrative Information | |
NCT Number ICMJE | NCT00080756 |
Other Study ID Numbers ICMJE | 02164, P30CA033572, CHNMC-IRB-02164, CDR0000355156 |
Has Data Monitoring Committee | No |
Responsible Party | City of Hope Medical Center |
Study Sponsor ICMJE | City of Hope Medical Center |
Collaborators ICMJE | National Cancer Institute (NCI) |
Investigators ICMJE | |
Information Provided By | City of Hope Medical Center |
Verification Date | October 2011 |
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |